Cargando…

Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis

BACKGROUND: Adults aged 18–64 years with comorbid conditions are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease. The 4 Pillars™ Practice Transformation Program (4 Pillars Program) increases uptake of pneumococcal polysaccharide va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wateska, Angela R., Nowalk, Mary Patricia, Zimmerman, Richard K., Smith, Kenneth J., Lin, Chyongchiou J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785845/ https://www.ncbi.nlm.nih.gov/pubmed/29370768 http://dx.doi.org/10.1186/s12879-018-2967-2

Ejemplares similares

Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis
por: Smith, Kenneth J., et al.
Publicado: (2021)

Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA
por: Smith, Kenneth J., et al.
Publicado: (2022)

Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults
por: France, Glenson, et al.
Publicado: (2018)

Differential Gene Expression Elicited by Children in Response to the 2015–2016 Live Attenuated vs. Inactivated Influenza Vaccine
por: Zimmerman, Richard, et al.
Publicado: (2017)

Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States
por: Michaelidis, Constantinos I, et al.
Publicado: (2014)

The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis
por: Michaelidis, Constantinos I., et al.
Publicado: (2016)

Factors associated with in-office influenza vaccination by U.S. pediatric providers
por: Lin, Chyongchiou Jeng, et al.
Publicado: (2013)

1055 Antibody Response to Intradermal and High Dose Influenza Vaccine in 2012-13 Among Adults Who Did and Did Not Respond to Standard Dose Vaccine in 2011-12
por: Sundaram, Maria, et al.
Publicado: (2014)

Using the 4 pillars™ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial
por: Lin, Chyongchiou J., et al.
Publicado: (2016)

LB12. A Randomized Controlled Trial of Antibody Response to 2018–2019 Cell-based vs. Egg-based Quadrivalent Inactivated Influenza Vaccine in Children
por: Moehling, Krissy, et al.
Publicado: (2019)

Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
por: Joo, Heesoo, et al.
Publicado: (2016)

Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children
por: Martin, Judith M, et al.
Publicado: (2018)

Flavonoid Intake in European Adults (18 to 64 Years)
por: Vogiatzoglou, Anna, et al.
Publicado: (2015)

Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50–64 Years, and At-Risk Adults Aged 19–64 Years
por: Choi, Min Joo, et al.
Publicado: (2022)

The impact of physical frailty on the response to inactivated influenza vaccine in older adults
por: Moehling, Krissy K., et al.
Publicado: (2020)

Trends in Utilization and Costs of BRCA Testing among Women Aged 18–64 Years in the United States, 2003–2014
por: Chen, Zhuo, et al.
Publicado: (2017)

650 Relative Vaccine Effectiveness of Live-Attenuated Versus Inactivated Influenza Vaccines in Children and Adolescents Aged 2–18 Years in Two Seasons – US Flu VE Network
por: Clippard, Jessie, et al.
Publicado: (2014)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years
por: Yogurtcu, Osman N., et al.
Publicado: (2023)

393. Healthcare and Out-of-Pocket Costs Associated With Clostridioides difficile Infection Among US Adults 18–64 Years of Age
por: Yu, Holly, et al.
Publicado: (2022)

The potential economic value of a ‘universal’ (multi‐year) influenza vaccine
por: Lee, Bruce Y., et al.
Publicado: (2011)

Deaths caused by injury among people of working age (18–64) are decreasing, while those among older people (64+) are increasing
por: Bäckström, D., et al.
Publicado: (2017)

Determinants of adult vaccination at inner-city health centers: A descriptive study
por: Nowalk, Mary Patricia, et al.
Publicado: (2006)

Comparison of local influenza vaccine effectiveness using two methods
por: Balasubramani, G.K., et al.
Publicado: (2021)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

1442. Pneumonia Hospitalizations Averted With 13-Valent Pneumococcal Conjugate Vaccination of Adults Aged 18–64 Years With Diabetes in the United States
por: Suaya, Jose, et al.
Publicado: (2018)

Standing orders for influenza and pneumococcal polysaccharide vaccination: Correlates identified in a national survey of U.S. Primary care physicians
por: Albert, Steven M, et al.
Publicado: (2012)

988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018
por: Flannery, Brendan L, et al.
Publicado: (2018)

Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design
por: Zimmerman, Richard K., et al.
Publicado: (2023)

Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis
por: Matthews, Ian, et al.
Publicado: (2020)

COVID-19 vaccine hesitancy January-May 2021 among 18–64 year old US adults by employment and occupation
por: King, Wendy C., et al.
Publicado: (2021)

2734. Lack of Influence of Early Exposure to Influenza A(H3N2) Viruses on Vaccine Effectiveness Against A(H3N2)-Associated Illness in US Children <18 Years, 2016–2018
por: Ladva, Chandresh N, et al.
Publicado: (2019)

Does influenza vaccination status change physician ordering patterns for respiratory viral panels? Inspection for selection bias
por: Balasubramani, G.K., et al.
Publicado: (2018)

Vaccine Criticism on the World Wide Web
por: Zimmerman, Richard K, et al.
Publicado: (2005)

Health Insurance Coverage by Occupation Among Adults Aged 18–64 Years — 17 States, 2013–2014
por: Boal, Winifred L., et al.
Publicado: (2018)

396. Incidence and Attributable Mortality of Clostridioides difficile Infection Among US Adults 18-64 Years of Age
por: Yu, Holly, et al.
Publicado: (2022)

Predictors of colorectal cancer screening in diverse primary care practices
por: Zimmerman, Richard K, et al.
Publicado: (2006)

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial
por: Gaglani, Manjusha, et al.
Publicado: (2022)

Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16–64 years in Puerto Rico
por: Ortiz, A.P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vf849km73r0m65qr0qgkgdvc5q